Core Viewpoint - The article discusses the innovative strategies employed by Baiaosaitu in antibody drug development, focusing on their dual-core platform of a human antibody library and a humanized mouse model library, which addresses key challenges in the industry and enhances drug development efficiency [6][12][33]. Group 1: Antibody Drug Development Challenges - The majority of failures in antibody drug development stem from mismatches between candidate antibody molecules and the complex human environment, as well as between preclinical animal models and actual disease mechanisms [5]. - Successful antibody drug development requires high-quality antibody molecules and humanized mouse models that accurately simulate human pathophysiological processes [6][10]. Group 2: Baiaosaitu's Innovative Approaches - Baiaosaitu's "Thousand Mice and Ten Thousand Antibodies" initiative aims to create a comprehensive human antibody sequence library, significantly improving the drug discovery process [8][10]. - The company has developed over 1,000 gene-edited models, including more than 1,700 humanized mouse models, establishing a leading position in the global market [16][18]. Group 3: Financial Performance and Growth - Baiaosaitu's revenue has shown a compound annual growth rate of 40.2% since 2020, with projected revenue of 980 million in 2024, reflecting strong growth [23][27]. - The company achieved profitability for the first time in 2024, with a net profit of 114 million in the first three quarters of 2025, indicating improved financial health [27][30]. Group 4: Market Position and Collaborations - Baiaosaitu has established partnerships with over 950 global clients, including all top ten pharmaceutical companies, highlighting its strong market presence [16][18]. - The company’s humanized mouse model library supports various disease areas, making it a crucial partner for pharmaceutical companies in preclinical evaluations [16][19].

本次发行上市的募集资金扣除发行费用后，将按轻重缓急顺序投资以下项目：药物早期研发服务平台建 设项目、抗体药物研发及评价项目、临床前研发项目以及补充流动资金，募集资金投资额合计11.85亿 元。 公司各类创新模式动物和细胞产品主要包括以免疫检查点及细胞因子/细胞因子受体为代表的靶点人源 化小鼠模型、重度免疫缺陷(B-NDG)小鼠及衍生产品模型、各类自发疾病模型、工具鼠及靶点敲除小鼠 等动物模型，靶点人源化改造的鼠源细胞系以及各类人源细胞系等细胞模型，涵盖肿瘤、自身免疫、代 谢和神经等疾病领域，可满足科研机构、制药企业等在靶点概念验证及机制研究、药物临床前体内外药 理药效筛选等方面的需求。 报告期各期，公司主营业务收入分别为5.33亿元、7.16亿元、9.8亿元以及6.21亿元，2022年度至2024年 度年复合增长率为35.56%，公司主营业务收入均直接或间接与公司核心技术相关。 百奥赛图(688796.SH)发布首次公开发行股票并在科创板上市招股意向书，此次首次公开发行股票4750 万股，公开发行股票的比例占本次发行后公司总股本的10.63%。初步询价日期为2025年11月25日，申 购日期为2025年11月 ...